-
EWTX Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Edgewise Therapeutics (EWTX)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.81 mm | 44.81 mm | 44.81 mm | 44.81 mm | 44.81 mm | 44.81 mm |
Cash burn (monthly) | (no burn) | (no burn) | 13.48 mm | 12.26 mm | 9.12 mm | 9.08 mm |
Cash used (since last report) | n/a | n/a | 57.40 mm | 52.23 mm | 38.86 mm | 38.65 mm |
Cash remaining | n/a | n/a | -12.59 mm | -7.42 mm | 5.95 mm | 6.16 mm |
Runway (months of cash) | n/a | n/a | -0.9 | -0.6 | 0.7 | 0.7 |
13F holders | Current |
---|---|
Total holders | 180 |
Opened positions | 54 |
Closed positions | 16 |
Increased positions | 57 |
Reduced positions | 45 |
13F shares | Current |
---|---|
Total value | 2.69 tn |
Total shares | 106.04 mm |
Total puts | 410.00 k |
Total calls | 2.17 mm |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 15.02 mm | $400.93 bn |
Ra Capital Management | 8.91 mm | $237.78 bn |
BlackRock | 6.39 mm | $170.64 bn |
Baker Bros. Advisors | 5.84 mm | $155.87 bn |
Novo Holdings A/S | 5.55 mm | $148.13 bn |
JHG Janus Henderson | 4.56 mm | $121.62 bn |
Vanguard | 4.52 mm | $120.53 bn |
Cormorant Asset Management | 3.41 mm | $90.92 bn |
Cormorant Global Healthcare Master Fund | 2.95 mm | $0.00 |
Frazier Life Sciences Management | 2.83 mm | $75.61 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Jan 25 | Joanne M. Donovan | Common Stock | Sell | Dispose S | No | No | 27.6263 | 25,000 | 690.66 k | 16,358 |
28 Jan 25 | Joanne M. Donovan | Common Stock | Option exercise | Acquire M | No | Yes | 7.08 | 25,000 | 177.00 k | 41,358 |
28 Jan 25 | Joanne M. Donovan | Stock Option Common Stock | Option exercise | Dispose M | No | No | 7.08 | 25,000 | 177.00 k | 175,000 |
21 Jan 25 | Robert Blaustein | Stock Options Common Stock | Grant | Acquire A | No | No | 27.39 | 160,000 | 4.38 mm | 160,000 |
21 Jan 25 | Robert Blaustein | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
30 Dec 24 | Alan J Russell | Common Stock | Sell | Dispose S | No | No | 27.3747 | 100,000 | 2.74 mm | 14,863 |
30 Dec 24 | Alan J Russell | Common Stock | Option exercise | Acquire M | No | Yes | 0.18 | 100,000 | 18.00 k | 114,863 |
30 Dec 24 | Alan J Russell | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.18 | 100,000 | 18.00 k | 1,356,780 |
24 Dec 24 | Marc Semigran | Common Stock | Sell | Dispose S | No | No | 30.0803 | 1,729 | 52.01 k | 6,716 |
24 Dec 24 | Marc Semigran | Common Stock | Sell | Dispose S | No | Yes | 29.6607 | 27,980 | 829.91 k | 8,445 |